NSPR InspireMD, Inc.
InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russ…
Industry Peers
Medical Devices| Headline | Source | Time |
|---|---|---|
Older | ||
 InspireMD (NSPR) Upgraded to Buy: Here's What You Should Know InspireMD (NSPR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). | ||
InspireMD Inc (NSPR) (Q2 2026) Earnings Call Highlights: Navigating Recall Challenges While ... Despite flat revenue and a widened net loss from recall-related charges, InspireMD's international growth and promising trial results for its CGuard platforms signal a strategic path forward. | ||
 InspireMD, Inc. Q2 2026 Earnings Call Summary Moby summary of InspireMD, Inc.'s Q2 2026 earnings call | ||
 InspireMD, Inc. (NSPR) Reports Q2 Loss, Beats Revenue Estimates InspireMD (NSPR) delivered earnings and revenue surprises of +15.00% and +7.33%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Alpha Cognition Inc. (ACOG) Reports Q2 Loss, Tops Revenue Estimates Alpha Cognition Inc. (ACOG) delivered earnings and revenue surprises of -2.56% and +41.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 908 Devices Inc. (MASS) Reports Q2 Loss, Tops Revenue Estimates 908 Devices (MASS) delivered earnings and revenue surprises of +21.43% and +5.92%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Lags Revenue Estimates Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of +8.82% and -0.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||